Pharma is boosting pipelines to avoid patent cliff

14th February 2015

Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors Service.

The firm that produces reports around the financial outlook of companies and countries says pharma has improved its pipelines of new drugs, but that potential losses due to patent expirations has also increased since mid-2013.

In its Global Pharmaceuticals Snapshot study, an analysis of changes in the key credit attributes of 16 companies since the last report in May 2013, Moody’s calculated that four companies: Eli Lilly, Amgen, Merck and AstraZeneca have strengthened their pipelines, with AstraZeneca showing the largest improvement.

Read more at source article

Leave a Reply

Your email address will not be published.

67 − 57 =

« back to posts